Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AusCann Group Holdings
Sydney, New South Wales, Australiaauscann.com.au ↗
- Ownership
- Private
- Employees
- ~27
- Development stage
- Other
01
Overview
AusCann has launched THC/CBD powder-based hard-shell capsules using the Neuvis platform for pain and related indications. Products include veterinary medicines CPAT-01 for pain/inflammation in dogs and DermaCann for skin/immune function in dogs.
- Therapeutic areas
- ImmunologyNeurologyDermatology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Canopy Growth (past collaboration)
Beyond the preview
Go deeper on AusCann Group Holdings.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AusCann Group Holdings.